A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).

Trial Profile

A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BV-ICE
  • Most Recent Events

    • 06 Dec 2016 Initial results (n=16) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Nov 2016 According to Seattle Genetics media release, data will be presented at the 58th American Society of Hematology (ASH) Annual Meeting Dec 2016.
    • 20 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top